疾病与抗精神病药对首发精神病皮质变薄的差异效应:随机安慰剂对照MRI研究
该三盲随机安慰剂对照MRI研究纳入62例未用药首发精神病患者和27名健康对照,随访12个月。安慰剂组较对照组出现广泛皮质变薄,而抗精神病药治疗组与对照组无显著差异,提示早期精神病皮质变薄是疾病相关现象而非药物所致。
要点
- 未用药首发精神病患者12个月内出现广泛皮质变薄,以额叶、扣带回和枕叶最明显。
- 接受第二代抗精神病药治疗的患者未检测到与健康对照显著的皮质厚度差异。
- 皮质变薄与症状变化无关联,且未集中于特定功能网络。
核心结论
- 首发精神病未用药患者在第一年出现广泛皮质变薄,接受抗精神病药者未见此现象,提示变薄为疾病相关而非药物医源性效应。
研究设计与样本
- 三盲随机安慰剂对照MRI研究,62例未用药首发精神病患者随机接受第二代抗精神病药或安慰剂6个月,随访至12个月时安慰剂组35例。
- 健康对照组基线27名、12个月时21名,于基线、3个月和12个月采集T1加权扫描。
主要发现
- 12个月内安慰剂组较对照组出现广泛皮质变薄(FDR校正p<.05),额叶、扣带回和枕叶效应最大。
- 抗精神病药治疗组与对照组之间未检测到显著差异。
- 变薄未集中于特定功能网络,但高度分化的konio皮质区相对受保护(pspin<.05 FDR校正)。
- 变薄空间分布与GABAA/BZ、5-HT1B、5-HT2A和H3受体的规范分布对齐(0.17<r<0.28;pspin<.05 FDR校正)。
- 未发现变薄与症状变化之间的关联。
关键数值与推荐
- 线性混合效应模型拟合超过160,000个皮质位点,检验疾病和抗精神病药相关厚度变化。
临床怎么用
- 结果支持早期精神病皮质变薄反映疾病进程,而非抗精神病药不良反应,有助于临床沟通药物安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cortical gray matter loss is a common finding in magnetic resonance imaging (MRI) studies of psychosis and can progress with ongoing illness. A major unresolved question concerns whether these changes are driven by the illness or represent iatrogenic effects of antipsychotics. METHODS: In a triple-blind, randomized, placebo-controlled MRI study, 62 antipsychotic-naïve people with first-episode psychosis (FEP) received a second-generation antipsychotic or placebo over 6 months (n = 35 at 12 months) alongside a healthy control group (n = 27 at baseline, n = 21 at 12 months). T1-weighted scans were collected at baseline, 3 months, and 12 months. Linear mixed-effects models fitted to >160,000 cortical loci examined illness- and antipsychotic-related thickness changes. We also examined whether cortical changes were enriched within functional networks or cytoarchitectonic classes and whether they spatially correlated with normative positron emission tomography receptor/transporter densities and transcriptomically imputed cell densities. RESULTS: Over 12 months, the placebo group showed widespread cortical thinning compared with the control group (false discovery rate [FDR]-corrected p < .05), with the largest effects in frontal, cingulate, and occipital areas. No significant difference was detected between patients treated with antipsychotics and control participants. Thinning was not concentrated within specific functional networks, but highly differentiated koniocortical areas were relatively protected (pspin < .05 FDR-corrected). Thinning spatially aligned with normative distributions of GABAA/BZ, 5-HT1B, 5-HT2A, and H3 receptors (0.17 <r < 0.28; pspin < .05 FDR-corrected). No associations between thinning and symptom change were identified. CONCLUSIONS: Widespread cortical thinning occurs over the first year of FEP in people not receiving antipsychotics. No such thinning is evident in patients receiving antipsychotics. These findings suggest that cortical thinning in early psychosis is an illness-related phenomenon.
引用
- Chopra S, Holmes A, Segal A, et al. Differential Effects of Illness and Antipsychotics on Cortical Thinning in First-Episode Psychosis: A Randomized, Placebo-Controlled Magnetic Resonance Imaging Study. Biol Psychiatry. 2026. PMID: 42690206. doi:10.1016/j.biopsych.2026.06.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。